近日，中山大学教授马骏及其团队报道了纳武单抗联合诱导化疗和放疗治疗鼻咽癌。相关论文发表在2025年2月27日出版的《癌细胞》杂志上。

在这项2期多中心PLATINUM试验（NCT03984357）中，课题组研究人员招募了152名NPC患者，他们接受了12个周期的纳武单抗诱导化疗和放疗，不同时使用顺铂。中位随访43个月后，3年无失败生存率（FFS）为88.5%(95%可信区间[CI]， 83.4%-93.8%)， 3年总生存率为97.9%。诱导期处理后EBV (Epstein-Barr virthem) DNA的早期清除与FFS益处相关。60例（40.2%）和8例（5.2%）患者分别发生急性和晚期3-4级不良事件（AEs）。大多数患者对AE相关频率（68.0% ~ 96.7%）、严重程度（56.0% ~ 98.6%）和干扰（58.0% ~ 98.0%）耐受性良好；86.7%-100.0%的生活质量领域显示无临床意义的恶化或快速恢复。纳武单抗诱导化疗和放疗对鼻咽癌患者具有抗肿瘤活性、低毒性、良好的耐受性和生活质量。

据悉，顺铂并发的严重毒副作用是鼻咽癌治疗中的一个关键问题。

附：英文原文

Title: Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: A multicenter phase 2 PLATINUM trial

Author: Cheng Xu, Guan-Qun Zhou, Wen-Fei Li, De-Sheng Hu, Xiao-Zhong Chen, Shao-Jun Lin, Feng Jin, Xin-Qiong Huang, Gang Peng, Jing Huang, Yuan Wu, Chang-Juan Tao, Ji-Bin Li, Ai-Hua Lin, Hong-Yun Zhao, Shu-Bin Hong, Hui-Ling Huang, Ling-Long Tang, Ying-Lin Peng, Ke-Fu Shi, Liu Chen, Li-Ping Qi, Kun-Yu Yang, Liang-Fang Shen, Ying Sun, Jun Ma

Issue&Volume: 2025-02-27

Abstract: Severe toxicities caused by concurrent cisplatin are a critical problem in nasopharyngeal carcinoma (NPC) treatment. In this phase 2 multicenter PLATINUM trial (NCT03984357), we recruited 152 NPC patients who received 12-cycle nivolumab plus induction chemotherapy and radiotherapy without concurrent cisplatin. After a median follow-up of 43 months, the 3-year failure-free survival (FFS) was 88.5% (95% confidence interval [CI], 83.4%–93.8%) and the 3-year overall survival was 97.9%. An early clearance of Epstein-Barr virus (EBV) DNA after induction-phase treatment was associated with FFS benefit. Sixty (40.2%) and eight (5.2%) patients had acute and late grade 3–4 adverse events (AEs), respectively. Most patients had good tolerance to AE-associated frequency (68.0%–96.7%), severity (56.0%–98.6%), and interference (58.0%–98.0%); 86.7%–100.0% of quality-of-life domains showed either no clinically meaningful deterioration or a rapid recovery. Nivolumab plus induction chemotherapy and radiotherapy demonstrated efficacious anti-tumor activity, low toxicity, and favorable tolerability and quality-of-life for NPC patients.

DOI: 10.1016/j.ccell.2025.01.014

Source: https://www.cell.com/cancer-cell/abstract/S1535-6108(25)00032-7